Sparton (SPA) Misses Q4 EPS by 10c; Appoints New CFO
Get Alerts SPA Hot Sheet
Join SI Premium – FREE
Sparton (NYSE: SPA) reported Q4 EPS of $0.65, $0.10 worse than the analyst estimate of $0.75. Revenue for the quarter came in at $126.4 million versus the consensus estimate of $122.81 million.
Sparton also announced that Joseph G. McCormack has been appointed as the Company’s new Chief Financial Officer, effective immediately.
Mr. McCormack most recently joined Sparton as a Senior Financial Consultant in June of 2015. Previously, he served as the Chief Financial Officer of Ingenient Technologies Inc., a global provider of embedded multimedia systems and solutions where he was responsible for the worldwide financial organization as well as to drive strategic initiatives. Mr. McCormack was also a partner with Ernst & Young LLP where he advised private equity firms and high-growth portfolio companies throughout their lifecycle.
Mr. McCormack has extensive experience with SEC reporting and technical accounting matters and has broad experience with high growth companies including acquisitions, integration, and divestitures. He is a registered certified public accountant and earned a Bachelor of Science degree from DePaul University.
“We are pleased to have Joe transition from financial consultant to the Chief Financial Officer role, ” said Cary Wood, President and CEO of Sparton. “Joe has held several challenging financial leadership roles and has excelled in many diverse areas. Having observed his financial leadership capabilities first-hand, he is more than qualified to serve as Sparton’s CFO and we are looking forward to leveraging his expertise for both the day-to-day financial operations of the Company and long-term strategic planning.”
For earnings history and earnings-related data on Sparton (SPA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Star Equity to acquire Harte Hanks for $5 per share in cash and stock
- Allarity reports Q2 2026 results, completes stenoparib manufacturing
- XTEND positions itself for U.S. drone tariff market shift
Create E-mail Alert Related Categories
Earnings, Management Changes, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share